Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arbutus Biopharma Cp (ABUS)

Arbutus Biopharma Cp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arbutus Biopharma Cp 701 VETERANS CIRCLE WARMINSTER PA 18974 USA

www.arbutusbio.com P: 267-469-0914 F: 267-282-0411

Description:

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.

Key Statistics

Overview:

Market Capitalization, $K 596,346
Enterprise Value, $K 570,056
Shares Outstanding, K 188,717
Annual Sales, $ 18,140 K
Annual Net Income, $ -72,850 K
Last Quarter Sales, $ 1,530 K
Last Quarter Net Income, $ -17,880 K
EBIT, $ -80,060 K
EBITDA, $ -78,660 K
60-Month Beta 1.98
% of Insider Shareholders 4.00%
% of Institutional Shareholders 43.79%
Float, K 181,168
% Float 96.00%
Short Volume Ratio 0.74

Growth:

1-Year Return 27.13%
3-Year Return -3.38%
5-Year Return 42.73%
5-Year Revenue Growth 204.87%
5-Year Earnings Growth 56.86%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.10 on 05/02/24
Next Earnings Date 08/01/24
Earnings Per Share ttm -0.44
EPS Growth vs. Prev Qtr 16.67%
EPS Growth vs. Prev Year 0.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-4 on 11/04/10

ABUS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -62.68%
Return-on-Assets % -47.22%
Profit Margin % -401.60%
Debt/Equity 0.00
Price/Sales 33.81
Price/Cash Flow N/A
Price/Book 5.09
Book Value/Share 0.64
Interest Coverage -157.37
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar